Entomophthorales is typically localised. 3, 5 This review focuses only on mucormycosis.
Mucormycosis may be acquired through different routes, including the respiratory tract, injured skin, contaminated needles or catheters, or ingestion of contaminated food. 7 The most common sites of infection are the rhino-orbital-cerebral, pulmonary, gastrointestinal and cutaneous areas. 4, 11, 13 Following the initial infection, the disease typically progresses quickly, with rapid invasion of blood vessels leading to thrombosis and tissue necrosis. 3, 7 A number of different factors are associated with an increased risk of mucormycosis. 5, 10 Globally, mucormycosis is particularly common in patients with diabetes mellitus, and the risk is much higher in patients with uncontrolled diabetes, in whom the resultant ketoacidosis interferes with the normal activity of lymphocytes, increasing risk of infection. 3, 4, 6, 7, [14] [15] [16] In addition, as with other IFD, patients with an impaired immune system following the use of immunosuppressive treatments are also vulnerable. This group includes patients receiving chemotherapy as treatment for cancer, especially haematological malignancies, and also hematopoietic stem cell transplantation (HSCT) and solid organ transplant (SOT) recipients. 3, 4, 6, 7, 16 Mucormycosis also affects immunocompetent individuals after penetrating trauma or burns, which exposes tissues to environmental sources of fungi, and patients with iron overload under treatment with deferoxamine. 3, 4, 6, 7, 16 Characteristically, fungi belonging to the order Mucorales exhibit high minimum inhibitory concentrations (MICs) to many antifungal agents currently available. 12 The antifungal agents with the lowest MICs for Mucorales are amphotericin B, isavuconazole and posaconazole, but the MICs vary widely depending on the genus and species. In the clinical setting, MICs of each antifungal agent for each genus and species need to be interpreted in the context of the antifungal exposures that are achievable. 17 Prompt diagnosis and rapid initiation of antifungal therapy combined with surgical removal of infected tissue are required for optimal outcomes. In addition, control of the underlying condition and/or reduction of immunosuppression are important components of treatment. 3, [12] [13] [14] As acknowledged by the European Confederation of Medical Mycology (ECMM), there are currently regional differences in the diagnosis and treatment of mucormycosis. As such, the ECMM has recently begun a "neglected orphan disease guidance initiative" focusing on this disease both within and beyond the European region. 18 Several previous studies have gathered data on mucormycosis in patients in Europe, Asia or other areas, [3] [4] [5] [8] [9] [10] [11] 19, 20 but to date, there has been no comprehensive review of the literature on mucormycosis in South America. Here, we collate and review mucormycosis case studies reported in South American countries, exploring patient characteristics, course of infection, treatment regimens and clinical outcomes.
| ME THODS
We performed a PubMed and Embase search of the medical literature through October 2018 using the following keywords: mucormycosis, mucor*, zygomycos*, zygomycet*, zigomicos*, zigomicet*, cigomicos*, cigomicet*, phycomycos*, ficomicos*, phicomicet*, ficomicet*, Mucorales, Rhizopus, Mucor, Rhizomucor, Saksenaea, Apophysomyces, Cunninghamella, Lichtheimia, Absidia, Syncephalastrum, plus the names of the individual South American countries. There were no language restrictions. Infections documented to be caused by fungi of the order Entomophthorales were excluded.
The publications identified in the search were screened manually to identify publications that included relevant information based on their abstracts and/or full text. We only included case reports for which all of the following information was described for each indi- Data were entered in Microsoft ® Excel ® 2010 and analysed using descriptive statistics only. Duplicates were identified within Excel and removed manually. Redundant cases appearing in more than one journal article were eliminated. Case series that summarised data across patients instead of reporting these data separately for each individual patient were excluded. Three such publications, all from Chile, were identified. [21] [22] [23] The authors confirm that the ethical policies of the journal, as noted on the journal's author guidelines page, have been adhered to.
No ethical approval was required as this is a review article with no original research data.
| RE SULTS
Literature searches identified cases of mucormycosis in 59 patients from Brazil and 84 from the wider South America region (Argentina, 36; Chile, 14; Colombia, 22; Venezuela, 7; Peru, 3; and Ecuador and French Guiana, 1 case each), with a total of 143 cases. Full reference lists are provided in the Supporting information. As around 41% of cases were from a single country, Brazil, these cases are presented separately to avoid skewing the results for the whole region in favour of a single country.
The earliest case was reported in April 1965, 24 and the latest case was reported in July 2018. 25 Only five cases were reported in the literature in the period between 1970 and 1979, but the number of published cases has increased with each subsequent decade, with 51 already published within the current decade. The number of deaths related to mucormycosis has also increased in parallel, but the overall mortality rate across all cases appears to have decreased Table 1 . After diabetes mellitus, the next most common conditions were SOT (22.0%) and malignancy (16.9%) in Brazil, and penetrating trauma/burns (32.1%) and malignancy (10.7%) in the other countries.
Of note, the incidence of penetrating trauma/burns as an underlying cause was much lower in Brazil than in the other countries (3.4% vs 32.1%). Thirteen of the 29 cases of penetrating trauma were from Colombia, and eight of these cases were skin and soft tissue infection after a volcanic eruption. 26 The overall mortality rate was 48.3%, 52.5% in Brazil and 45.2% in the other countries. The mortality rate Table 4 ). Patients identified in our literature searches were of comparable age (median 40 years) to those reported from a global review (median 39 years). 11 However, our median patient age was younger than that observed in Europe-wide and global studies (median 50 and 49 years, respectively), 4, 10 or studies in specific countries such as France and Italy (median 58 and 60 years, respectively). 9, 19 Most cases in South America occurred in the 18-44 years and 45-64 years age groups (74.8%). Additionally, most patients were males (61.5%),
| D ISCUSS I ON
which is also consistent with findings (60%-70% male) across studies from other regions. 4, [9] [10] [11] 14, 19 Overall, our data on underlying conditions and mortality are broadly consistent with published studies. 4, 5, 7, 10, 11 Diabetes mellitus was the most frequent underlying condition in South America, followed by penetrating trauma or burns, malignancy and SOT. This is largely consistent with previous reports from other regions. 3, 4, 6, 11, 15 Despite an increase in the prevalence of diabetes in South America during the study period, 27 11 and also our personal experience in this area, which indicates that the primary determinant of outcome is the immune status of the host.
The most frequent sites of infection were, in order, rhino-sino-orbito-cerebral, skin/soft tissues and pulmonary. Diabetes mellitus and malignancy were mostly associated with rhino-sino-orbito-cerebral infections, while penetrating trauma or burns were mostly associated with skin and soft tissue infections. This is also mostly consistent with previous reports from other regions, 3, 4, 6, 15 although malignancies have been associated with pulmonary infections in previous reports. 11 Further analysis of the types of malignancies observed may clarify the cause of this discrepancy.
Pulmonary infections were more frequently observed in Brazil conclusions. In addition, it is not possible to discern the causes for some of the patterns observed, such as the varying mortality rates with different sites of infection or with different underlying conditions. These issues may be addressed in future research as more cases are reported.
This case review identifies patterns of infection in South
America that are of value to physicians in the region and may aid in formulating preventative efforts against mucormycosis. It also identifies gaps in current practice that, if addressed, could improve treatment across the region. Overall, increasing use of antifungals and surgery has much improved the prognosis of mucormycosis.
However, mortality remains high, particularly in patients where surgery is not performed. 7, 12, 14, 30 A combination of new diagnostic technologies, optimised use of available antifungal options, development of new antifungal agents and more aggressive public health policies may help to reduce mortality rates from mucormycosis in South America.
